Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share transaction and does not contain financial statements or performance metrics.
Material Changes
The only material change disclosed is a transaction involving a Person Discharging Managerial Responsibility:
- Individual: Mr. M Dunoyer
- Date of Transaction: March 15, 2013
- Action: Sale of 41,961 Ordinary Shares
- Price: 1,494.15 pence per Ordinary Share
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of the share sale mentioned above.
Investor Verification Checklist
- Verify the total shareholding of Mr. M Dunoyer following the sale of 41,961 shares.
- Confirm the market price of GSK shares on March 15, 2013, to contextualize the sale price of 1,494.15 pence.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance data, as this 6-K does not contain it.